InsiderTrades.com logo
Tiny Biotech Stock Wins $75 Billion Patent
From Behind the Markets   |   Ad
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Find out more here >>>
Johanna Mercier net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Johanna Mercier Biography and Net Worth

Insider of Gilead Sciences
Johanna Mercier serves as Gilead's Chief Commercial Officer, with responsibility for the global commercialization of all the company's medicines throughout the product lifecycle. Under her leadership, Gilead works to ensure that patients around the world have access to the company's transformational medicines.

Johanna joined Gilead in 2019 after 25 years at Bristol-Myers Squibb, where she served in a number of executive leadership positions, gaining broad experience across geographies and in all aspects of the commercial business. In her time there, she successfully evolved the culture and drove strong commercial execution with double-digit growth and multiple launches that changed the standard of care in melanoma and renal cancers.

Johanna holds a bachelor's degree in biology from the University of Montreal and an MBA from Concordia University.

She currently serves on the board of directors of Neurocrine Biosciences, Inc. and the University of Southern California's Leonard D. Schaeffer Center for Health Policy and Economics.

What is Johanna Mercier's net worth?

The estimated net worth of Johanna Mercier is at least $5.52 million as of January 9th, 2024. Ms. Mercier owns 82,729 shares of Gilead Sciences stock worth more than $5,522,988 as of April 19th. This net worth estimate does not reflect any other investments that Ms. Mercier may own. Additionally, Ms. Mercier receives an annual salary of $3,100,000.00 as Insider at Gilead Sciences. Learn More about Johanna Mercier's net worth.

How old is Johanna Mercier?

Ms. Mercier is currently 54 years old. There are 7 older executives and no younger executives at Gilead Sciences. The oldest executive at Gilead Sciences is Dr. Rudolf Ertl, Senior Vice President of Commercial Operations of Australia, Canada, Europe, who is 78 years old. Learn More on Johanna Mercier's age.

What is Johanna Mercier's salary?

As the Insider of Gilead Sciences, Inc., Ms. Mercier earns $3,100,000.00 per year. The highest earning executive at Gilead Sciences is Mr. Daniel P. O'Day, Chairman & CEO, who commands a salary of $6,990,000.00 per year. Learn More on Johanna Mercier's salary.

How do I contact Johanna Mercier?

The corporate mailing address for Ms. Mercier and other Gilead Sciences executives is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. Gilead Sciences can also be reached via phone at (650) 574-3000 and via email at [email protected]. Learn More on Johanna Mercier's contact information.

Has Johanna Mercier been buying or selling shares of Gilead Sciences?

Johanna Mercier has not been actively trading shares of Gilead Sciences during the last quarter. Most recently, Johanna Mercier sold 8,242 shares of the business's stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $85.23, for a transaction totalling $702,465.66. Following the completion of the sale, the insider now directly owns 82,729 shares of the company's stock, valued at $7,050,992.67. Learn More on Johanna Mercier's trading history.

Who are Gilead Sciences' active insiders?

Gilead Sciences' insider roster includes Gregg Alton (EVP), Paul Carter (EVP), John Cogan (Director), Andrew Dickinson (Exec. VP & CFO ), Andrew Dickinson (CFO), John Martin (Director), Johanna Mercier (Insider), James Meyers (EVP), John Milligan (Insider), Daniel O'Day (Chairman & CEO ), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Robin Washington (CFO), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.

Are insiders buying or selling shares of Gilead Sciences?

In the last year, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 30,228 shares worth more than $2,453,404.15. The most recent insider tranaction occured on April, 1st when insider Merdad Parsey sold 2,000 shares worth more than $145,920.00. Insiders at Gilead Sciences own 0.2% of the company. Learn More about insider trades at Gilead Sciences.

Information on this page was last updated on 4/1/2024.

Johanna Mercier Insider Trading History at Gilead Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/9/2024Sell8,242$85.23$702,465.6682,729View SEC Filing Icon  
See Full Table

Johanna Mercier Buying and Selling Activity at Gilead Sciences

This chart shows Johanna Mercier's buying and selling at Gilead Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Gilead Sciences Company Overview

Gilead Sciences logo
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $66.76
Low: $66.16
High: $66.83

50 Day Range

MA: $72.10
Low: $66.16
High: $75.94

2 Week Range

Now: $66.76
Low: $65.90
High: $87.86

Volume

10,656,158 shs

Average Volume

7,352,060 shs

Market Capitalization

$83.12 billion

P/E Ratio

14.84

Dividend Yield

4.60%

Beta

0.19
Tiny Biotech Stock Wins $75 Billion Patent
From Behind the Markets   |   Ad
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Find out more here >>>